Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-03-14
2006-03-14
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07012074
ABSTRACT:
There is provided compounds of formula (I), wherein R1, R2and Rato Rbhave meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
REFERENCES:
patent: 3281421 (1966-10-01), Cignarella et al.
patent: 3328396 (1967-06-01), Kirchner et al.
patent: 3962449 (1976-06-01), Binnig et al.
patent: 4459301 (1984-07-01), Binnig et al.
patent: 4550112 (1985-10-01), Schoen et al.
patent: 4556662 (1985-12-01), Binnig et al.
patent: 4571396 (1986-02-01), Hutt et al.
patent: 4780468 (1988-10-01), Bridges et al.
patent: 5140033 (1992-08-01), Schriewer et al.
patent: 5468858 (1995-11-01), Berlin et al.
patent: 14 45 993 (1962-06-01), None
patent: 37 02 393 (1987-01-01), None
patent: 37 21 745 (1987-07-01), None
patent: 0 136 945 (1985-04-01), None
patent: 0 157 174 (1985-10-01), None
patent: 0 230 274 (1987-07-01), None
patent: 0 251 308 (1988-01-01), None
patent: 0 266 576 (1988-05-01), None
patent: 0 304 087 (1989-02-01), None
patent: 0 306 871 (1989-03-01), None
patent: 0 308 843 (1989-03-01), None
patent: 0 393 400 (1990-10-01), None
patent: 0 470 578 (1992-02-01), None
patent: 0 596 126 (1994-05-01), None
patent: 0 614 664 (1994-09-01), None
patent: 0 665 228 (1995-08-01), None
patent: 0 700 912 (1996-03-01), None
patent: 0 825 186 (1998-02-01), None
patent: 2099683 (1972-03-01), None
patent: 2 531 709 (1984-02-01), None
patent: 949088 (1964-02-01), None
patent: 1180060 (1970-02-01), None
patent: 2 295 387 (1996-05-01), None
patent: WO 88/02627 (1988-04-01), None
patent: WO 91/07405 (1991-05-01), None
patent: WO 93/20078 (1993-10-01), None
patent: WO 94/16698 (1994-08-01), None
patent: WO 95/18129 (1995-07-01), None
patent: WO 95/23152 (1995-08-01), None
patent: WO 96/04254 (1996-02-01), None
patent: WO 96/33172 (1996-10-01), None
patent: WO 9635686 (1996-11-01), None
patent: WO 99/31100 (1999-06-01), None
patent: WO 00/59510 (2000-10-01), None
Crijns et al, “Atrial Flutter can be Terminated by a Class III Antiarrhythmic Drug but not by a Class IC Drug” European Heart Journal, vol. 15(10), pp. 1403-1408 (Oct. 1994).
Foster et al, “Ibutilide: A Review of its Pharmacological Properties and Clinical Potential in the Acute Management of Atrial Flutter and Fibrillation” Drugs, vol. 54(2), pp. 312-330 (Aug. 1997).
Kellow, “Motility-Like Dyspepsia” the Medical Journal of Australia, vol. 157, pp. 385-388 (1992).
Stoddard et al, “Electrical Arrhythmias in the Human Stomach” Gut, vol. 22, pp. 705-712 (1981).
Corvert® (ibutilide fumarate injection) Prescribing Information © 2002 Pharmacia & Upjohn Company.
Tikosyn® (dofetilide) Prescribing Information © 2004 Pfizer Labs.
Cignarella, G. et al; “Benzocondensed derivatives as rigid analogues of the μ-opioid agonist 3(8)-cinnamyl-8(3)-propionyl-3,8-diazabicyclo[3.2.1]octanes: synthesis, modeling, and affinity” Table 1;IL Farmaco53 pp. 667-674 (1998).
Barlocco, D. et al.; “Mono- and Disubstituted-3,8-diazabicyclo[3.2.1]octane Derivatives as analgesics Structurally Related to Epibatidine: Synthesis, Activity, and Modeling”; Table 1, Scheme 2;J. Med. Chem., 41, pp. 674-681 (1998).
“The Cardiac Arrhythmia Suppression Trial (CAST)”; reported inNew England Journal of Medicine, 321, No. 6, pp 406-412 (1989).
Garrison, G.L., et al; “Novel 3,7-Diheterabicyclo[3.3.1]nonanes That Possess Perdominant Class III Antiarrhythmic Activity in 1-4 Day Post Infraction Dog Models: X-ray Diffraction Analysis of 3-[4-(1 H -Imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nonane Dihydroperchlorate”;J. Med. Chem.; 39, pp. 2559-2570 (1996).
Paroczai, M., et al; “Investigations to Characterize a New Antiarrhythmic Drug Bisaramil”;Pharmacological Research; 24, No. 2, pp. 149-162 (1991).
Wang, J., et al; “Class III Antiarrhythmic Drug Action in Experimental Atrial Fibrillation”;Circulation, 90, pp. 2032-2041 (1994).
Chen, C.L. et al; “High-Performance Liquid Chromatographic Determination of SAZ-VII-22, a Novel Antiarrhythmic Agent, in Dog Plasma and Urine”;Analytical Sciences;9, pp. 429-431 (1993).
Fontanella, L. et al; “Analoghi Biciclici Della Piperazina”;IL Farmaco—Ed. Sci.; vol. 27(9), pp. 755-772, (1972).
Fontanella, L. et al; “Analoghi Biciclici Della Piperazina”;IL Farmaco—Ed. Sci.; vol. 30(9), pp. 742-753, (1975).
Occelli, E. et al; “Omologhi Biciclici Della Piperazina”;IL Farmaco—Ed. Sci.; vol. 33(6), pp. 402-420, (1978).
Occelli, E., et al; “Omologhi Triciclici Della Piperazina”;IL Farmaco—Ed. Sci, vol. 33(11), pp. 875-884, (1978).
Occelli, E., et al; “Sintesi Ed Attivita Farmacologica Di Derivati Di 3-Aminopropiofenoni E DI 3-Aminometiilcanfore”;IL Farmaco—Ed. Sci.; vol. 40(2), pp. 86-101, (1985).
Cignarella, G., et al; “Interaction of 3,8-Diazabicyclo (3.2.1) Octanes with Mu and Delta Opioid Receptors”;Pharmacol. Res. Commun.; vol. 20, No. 5, pp. 383-394 (1988).
Barlocco, E., et al; “Synthesis and μ-opioid receptor affinity of a new series of nitro substituted 3,8-diazabicyclo[3.2.1]octane derivatives”;IL Farmaco53, pp. 557-562, (1998).
Sturm, P.A., et al; “Antifilarial Agents. Diazabicyclooctanes and Diazabicycloheptanes as Bridged Analogs of Diethylcarbamazine”;Journal of Medicinal Chemistry; vol. 17, No. 5, pp. 481-487 (1974).
Occelli, E., et al; “Analoghi Biciclici Della Piperazina”;IL Farmaco—Ed Sci.; vol. 32(4), pp. 237-247 (1977).
Cignarella, G., et al; “Strutture tricicliche derivanti dal 3,8-diazabiciclo[3.2.1] ottano.—Nota I. Sintesi e proprieta del 3,8-diazatriciclo[3.2.1.23.8]decano.”;Gazz. Chim. Ital.; vol. 98(7), pp. 848-860 (1968).
Pifferi, G., et al; “1H-2,3-Benzoxazine and Derivatives-IIIτ”;Tetrahedron, vol. 24, pp. 4923-4932 (1968).
Barlocco, D., et al; “Synthesis and Opioid receptor affinity of Bivalent Ligands Derived from 3,8-Diazabicyclo(3.2.1)Octanes”;IL Farmaco, vol. 48(3), pp. 387-396, (1993).
Garrison, G.L., et al; “Novel 3,7-Diheterabicyclo[3.3.1]nonanes That Possess Predominant Class III Antiarrhythmic Activity in 1-4 Day Post Infraction Dog Models: X-ray Diffraction Analysis of 3-[4-(1 H -Imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nonane Dihydroperchlorate”;J. Med. Chem.; 39, pp. 2559-2570 (1996).
Axenborg, J.E. et al; “A PC-based on-line system for physiological in vivo and in vitro experiments”;Computer Methods and Programs in Biomedicine, 41, pp. 55-67 (1993).
Bjorsne Magnus
Hoffmann Kurt-Jürgen
Pontén Fritiof
Strandlund Gert
Svensson Peder
AstraZeneca AB
Nixon & Vanderhye
Tucker Zachary C.
Wilson James O.
LandOfFree
3,8-Diazabicyclo[3.2.1]octanes and their use in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,8-Diazabicyclo[3.2.1]octanes and their use in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,8-Diazabicyclo[3.2.1]octanes and their use in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3562525